Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9031258 | 0.84 | SMN1; SMN2 (0.40) | MEN1KMT2ASIGMAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28078678 | 0.83 | USP2 (0.45) | MEN1KMT2ASIGMAR1SMN1; SMN2MAPT | |
| SCHEMBL25305931 | 0.79 | SIGMAR1 (0.41) | MEN1KMT2ASIGMAR1SMN1; SMN2ALDH1A1 | |
| Piperazine SCHEMBL17912476 | 0.77 | DGAT1 (0.33) | KMT2ASMN1; SMN2HSD17B10LMNANR1H2 | |
| SCHEMBL27885590 | 0.77 | SIGMAR1 (0.41) | MEN1KMT2ASIGMAR1SMN1; SMN2ALDH1A1 | |
| Tert-Butyl Formate SCHEMBL27718748 | 0.76 | TDP1 (0.42) | MEN1KMT2ASIGMAR1SMN1; SMN2ALDH1A1 | |
| Acetic Acid SCHEMBL19347190 | 0.76 | KMT2A (0.42) | MEN1KMT2ASIGMAR1SMN1; SMN2ALDH1A1 | |
| Acetic Acid SCHEMBL8411514 | 0.76 | KMT2A (0.42) | MEN1KMT2ASIGMAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6600492 | 0.76 | MEN1 (0.41) | MEN1KMT2ASIGMAR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18729437 | 0.76 | MEN1 (0.41) | MEN1KMT2ASIGMAR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH HOLDINGS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| CN-1550496-A | Acetylenic alpha-amino acid-based sulfamide hydroxamic acid TACE inhibitors | ���Ͽع�����˾ | 2004-12-01 | — | — | CN | disclosed |
| US-6812227-B2 | SULFUR COMPOUNDS SUCH AS 2-((4-BUT-2-YNYLOXY-BENZENESULFONYL)-METHYL-AMINO)-N-HYDROXY-3-METHYL -BUTYRAMIDE, USED AS TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) INHIBITORS, FOR PROPHYLAXIS OF RHEUMATIC DISEASES, SEPSIS OR INFLAMMATION | WYETH HOLDINGS CORPORATION | 2004-11-02 | — | — | US | disclosed |
| EP-1144368-B1 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6716833-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE AND DEGENERATIVE CARTILAGE LOSS. | WYETH HOLDINGS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | disclosed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | disclosed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
| CN-1345308-A | Acetylenic alpha-amino acid based sulfonamide hydroxamic acid TACE inhibitors | AMERICAN CYANAMID CO (US) | 2002-04-17 | — | — | CN | disclosed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | MEN1 2930/4885KMT2A 2103/4885SIGMAR1 2868/4885 |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | MEN1 2930/4885KMT2A 2103/4885SIGMAR1 2868/4885 |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | MEN1 2930/4885KMT2A 2103/4885SIGMAR1 2868/4885 |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, MMP12 | MEN1 3334/4885KMT2A 1673/4885SIGMAR1 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.